This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Opiant Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Opiant Pharmaceuticals's earnings have been declining at an average annual rate of -22.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 10.3% per year.
Informations clés
-22.2%
Taux de croissance des bénéfices
-10.7%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | 10.3% |
Rendement des fonds propres | -161.4% |
Marge nette | -148.1% |
Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Ventilation des recettes et des dépenses
Comment Opiant Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Sep 22 | 22 | -33 | 24 | 0 |
30 Jun 22 | 39 | -20 | 23 | 0 |
31 Mar 22 | 46 | -6 | 20 | 0 |
31 Dec 21 | 48 | 3 | 17 | 0 |
30 Sep 21 | 44 | 2 | 16 | 0 |
30 Jun 21 | 37 | -1 | 16 | 0 |
31 Mar 21 | 32 | -3 | 16 | 0 |
31 Dec 20 | 30 | -2 | 16 | 0 |
30 Sep 20 | 27 | 0 | 15 | 0 |
30 Jun 20 | 39 | 10 | 15 | 0 |
31 Mar 20 | 39 | 12 | 13 | 0 |
31 Dec 19 | 41 | 12 | 13 | 0 |
30 Sep 19 | 38 | 1 | 12 | 0 |
30 Jun 19 | 21 | -11 | 12 | 0 |
31 Mar 19 | 18 | -14 | 12 | 0 |
31 Dec 18 | 14 | -21 | 11 | 0 |
30 Sep 18 | 34 | -2 | 18 | 0 |
30 Jun 18 | 29 | -5 | 17 | 0 |
31 Mar 18 | 30 | -3 | 16 | 0 |
31 Dec 17 | 28 | 3 | 15 | 0 |
31 Oct 17 | 17 | 2 | 11 | 4 |
31 Jul 17 | 18 | 7 | 8 | 0 |
30 Apr 17 | 15 | 6 | 7 | 2 |
31 Jan 17 | 18 | 9 | 5 | 3 |
31 Oct 16 | 11 | 3 | 5 | 3 |
31 Jul 16 | 10 | -8 | 15 | 3 |
30 Apr 16 | 10 | -8 | 15 | 4 |
Des revenus de qualité: OPNT is currently unprofitable.
Augmentation de la marge bénéficiaire: OPNT is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OPNT is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accélération de la croissance: Unable to compare OPNT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: OPNT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Rendement des fonds propres
ROE élevé: OPNT has a negative Return on Equity (-161.39%), as it is currently unprofitable.